J. Garland
Director/Board Member presso CALITHERA BIOSCIENCES, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Mr. J.
S.
Garland is an Independent Director at Olema Pharmaceuticals, Inc., an Independent Director at Day One Biopharmaceuticals, Inc. and an Independent Director at Calithera Biosciences, Inc. He is on the Board of Directors at Olema Pharmaceuticals, Inc., ALX Oncology Holdings, Inc., Day One Biopharmaceuticals, Inc. and Calithera Biosciences, Inc. Mr. Garland was previously employed as a Chief Executive Officer & Director by PACT Pharma, Inc., a President, Chief Executive Officer & Director by Portola Pharmaceuticals LLC, an Independent Director by Karyopharm Therapeutics, Inc., a President by Relypsa, Inc., a Chief Commercial Officer by Exelixis, Inc., a Vice President-Avastin Franchise by Genentech, Inc., and a Head-Sales & Marketing Division by Amgen, Inc. He received his undergraduate degree from California Polytechnic State University (San Luis Obispo) and an MBA from The Fuqua School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 22/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
| 20/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
| 30/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
| 16/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di J. Garland
| Società | Posizione | Inizio |
|---|---|---|
| CALITHERA BIOSCIENCES, INC. | Director/Board Member | 10/07/2020 |
| DAY ONE BIOPHARMACEUTICALS, INC. | Director/Board Member | 17/08/2021 |
| ALX ONCOLOGY HOLDINGS INC. | Director/Board Member | 28/11/2022 |
| OLEMA PHARMACEUTICALS, INC. | Director/Board Member | 16/10/2023 |
Precedenti posizioni note di J. Garland
| Società | Posizione | Fine |
|---|---|---|
PACT Pharma, Inc.
 PACT Pharma, Inc. Pharmaceuticals: MajorHealth Technology PACT Pharma, Inc. develops pharmaceutical products. It offers personalizes adoptive cell therapies with neoantigen-targeted T cells against cancer. The company is headquartered in South San Francisco, CA. | Chief Executive Officer | 01/02/2023 |
| PORTOLA PHARMACEUTICALS, INC. | Chief Executive Officer | 01/07/2020 |
| KARYOPHARM THERAPEUTICS INC. | Director/Board Member | 21/05/2020 |
| RELYPSA INC | President | 01/10/2018 |
| EXELIXIS, INC. | Corporate Officer/Principal | 31/10/2014 |
Formazione di J. Garland
| California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
| The Fuqua School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 6 |
|---|---|
| AMGEN INC. | Health Technology |
| EXELIXIS, INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| CALITHERA BIOSCIENCES, INC. | Health Technology |
| OLEMA PHARMACEUTICALS, INC. | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
PACT Pharma, Inc.
PACT Pharma, Inc. Pharmaceuticals: MajorHealth Technology PACT Pharma, Inc. develops pharmaceutical products. It offers personalizes adoptive cell therapies with neoantigen-targeted T cells against cancer. The company is headquartered in South San Francisco, CA. | Health Technology |
| ALX Oncology Holdings, Inc. |
- Borsa valori
- Insiders
- J. Garland
